Sobi® and Apellis Pharmaceuticals today announced the European Medicines Agency (EMA) has validated an indication extension application for Aspaveli® (pegcetacoplan) for the treatment of C3 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback